Inactive Instrument

Highlights Otonomy

Equities

OTIC

US68906L1052

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Otonomy Shares to be Suspended From Nasdaq Trading	22-12-22	MT
Otonomy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Otonomy, Inc Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss	22-10-13	CI
Otonomy Reports Results from Phase 2 Clinical Trial of Oto-313 in Patients with Tinnitus	22-08-01	CI
Otonomy, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-25	CI
Earnings Flash (OTIC) OTONOMY Reports Q1 Loss $-0.20, vs. Street Est of $-0.20	22-05-09	MT
Otonomy, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-09	CI
Otonomy, Inc. Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss	22-04-20	CI
Earnings Flash (OTIC) OTONOMY Posts Q4 Loss $-0.20, vs. Street Est of $-0.18	22-02-28	MT
Otonomy, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Otonomy, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-28	CI
Otonomy, Inc. Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus	22-02-22	CI
Otonomy Reports Corporate and Product Pipeline Update	22-01-06	CI
Otonomy Narrows Q3 Net Loss; Expects Enough Liquidity to Fund Operations Until Late 2023	21-11-10	MT
Otonomy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Otonomy, Inc. Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313	21-10-12	CI
Otonomy, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-04	CI
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for Oto-413 in Hearing Loss	21-06-15	CI
ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. for $0.8 million.	21-06-02	CI
Applied Genetic Technologies : Otonomy's OTO-825 Gene Therapy Saves Hearing Loss in Preclinical Models	21-05-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Otonomy

Equities

OTIC

US68906L1052

Highlights

Filters